Vipul Devas

Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO)

Ronald Emkey, William Koltun, Kathleen Beusterien et al. · Current Medical Research and Opinion · 2005 · 171 citations

Medicine, Pharmacology, Pharmacotherapy +16

Association between pathologic response and survival after neoadjuvant therapy in lung cancer

Julie S. Deutsch, Ashley Cimino‐Mathews, Elizabeth D. Thompson et al. · Nature Medicine · 2023 · 162 citations · Full text

Medicine, Oncology, Pharmacology +17

Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II)

Peyman Hadji, H. W. Minne, Michael Pfeifer et al. · Joint Bone Spine · 2008 · 64 citations

Medicine, Endocrinology, Pharmacotherapy +12

Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis

Solange Peters, Luis Paz‐Ares, Martin Reck et al. · Journal of Thoracic Oncology · 2024 · 23 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study.

Mariano Provencio, Mark M. Awad, Jonathan Spicer et al. · Journal of Clinical Oncology · 2024 · 21 citations

Medicine, Oncology, Perioperative Medicine +12